56 results about "Anti-Herpes simplex virus IgG" patented technology

The invention relates to the technical field of biology, and discloses anti-herpes simplex virus polypeptide and its application. Tests show that the anti-herpes simplex virus polypeptide has a high efficiency inhibition effect to the herpes simplex virus propagation, and the anti-herpes simplex virus polypeptide is used for producing the medicines for treating and preventing diseases related to herpes simplex. The invention provides a medicinal preparation which takes the anti-herpes simplex virus polypeptide as the effective component for treating the herpes caused by the herpes simplex virus, and has a obvious effectiveness for treating herpes, the effective rate for treating herpes simplex, labial herpes and genital herpes can reach to 100%. And the anti-herpes simplex virus polypeptide has low recurrence rate after heal and no toxic side effect.

The invention discloses a pharmaceutical composition for resisting herpes simplex virus and its preparing process, wherein the composition is prepared from coptis root, gentian root, pipewort, baras camphor by a predetermined weight ratio, the obtained active constituent has the actions of reducing fever, purging the intense heat and detoxicating. The composition can be prepared into eye drops, nose spray and electuary.

The invention provides antibodies and polypeptides that specifically bind to the glycoprotein D of herpes simplex virus (HSV) and use of the antibodies and polypeptides for treating or diagnosing HSV infections.

The invention relates to a recombinant HSV (Herpes Simplex Virus) amplicon vector and application thereof. By using two replication deficient adenoviruses respectively carrying Cre and an operative linked component loxP-HSVoriS-pac-transgenic expression box-loxP, a novel HSV amplicon vector is recombined in a coinfection cell. Being different from the traditional HSV amplicon vector taking bacterial plasmids as a skeleton, the amplicon vector does not contain a bacteria copying sequence (colEorigin) and a resistance gene component and only contains oriS of HSV, a pac sequence and a transgenic expression box. The recombinant HSV amplicon vector disclosed by the invention is used for preparing a novel HSV amplicon vector, which does not contain the bacterial gene component and is used for various types of transgenic researches and tumour gene treatments, and preparing an adenovirus treatment preparation for specific anti-HSV virus and related diseases. The HSV amplicon vector recombined by the replication deficient adenovirus of the preparation in cells replicates itself by using infected wild HSV virus and competitively inhibits or permanently expresses the antiviral genes so as to inhibit replication of wild HSV virus. Therefore, the recombinant HSV amplicon vector can be used for resisting HSV infection and treating related diseases thereof.

The invention discloses an application of fresh euphorbia helioscopia juice in the preparation of a medicine for resisting herpes simplex virus. A large number of experimental screening and experimental results prove that the fresh euphorbia helioscopia juice has a significant effect of inhibiting the cytopathic effect caused by the herpes simplex virus in vitro. The fresh euphorbia helioscopia juice has low toxicity and can lead to slight adverse reactions. The euphorbia helioscopia resources are wide and easy to obtain, have low cost and wide application prospect, can be developed sustainably and are expected to be developed into the medicine for resisting the herpes simplex virus.

The invention provides application of 1,2,3,4,6-penta-O-galloyl-b-D-glucose in preparing a medicine for resisting herpes simplex viruses, and in particular relates to application of the 1,2,3,4,6-penta-O-galloyl-b-D-glucose in preparing a medicine for resisting herpes simplex virus type 1. The 1,2,3,4,6-penta-O-galloyl-b-D-glucose has the function of preventing and treating cells infected by HSV-1, can also reduce the infectivity of the HSV-1 on MRC-5 cells, has the function of directly killing the HSV-1, and can reduce the activity of MRC-5 cells infected by the HSV-1; and the medicine for resisting the herpes simplex virus type 1 prepared by taking the 1,2,3,4,6-penta-O-galloyl-b-D-glucose as an effective ingredient has high suppression ratio on the herpes simplex virus type 1 within a safe dosage range, has strong function of preventing infection of the herpes simplex virus type 1, quickly cures patients, can relieve syndromes of infected patients, and has low toxicity and good stability.

The invention provides application of myricetin in preparing medicines and health products for preventing and treating diseases caused by herpes simplex virus. Experiments prove that the myricetin hasthe inhibitory activity on herpes simplex virus infection, has the activity of resisting HSV-1 and HSV-2, and has extremely low toxicity. The protein and mRNA expression of HSV-1 and HSV-2 were significantly inhibited by myricetin treatment. The action mechanism of the myricetin for resisting herpes simplex virus infection is that the myricetin directly interacts with HSV particles to interfere virus adsorption and virus-induced membrane fusion. Experiments prove that the myricetin can be developed into a novel target virus particle anti-HSV preparation and has good market application prospect.

The invention discloses a pharmaceutical composition for resisting herpes simplex virus and its preparing process, wherein the composition is prepared from coptis root, gentian root, pipewort, baras camphor by a predetermined weight ratio, the obtained active constituent has the actions of reducing fever, purging the intense heat and detoxicating. The composition can be prepared into eye drops, nose spray and electuary.

The invention discloses houttuynoids and a preparation method and application thereof. The houttuynoids have a structural formula as represented by formula (I) which is described in the invention; in the formula (I), R1 is represented by formula (I), formula (II), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), formula (IX) or formula (X) as described in the invention, and R2 is hydrogen or is represented by formula (XI), formula (XII), formula (XIII) or formula (XIV) as described in the invention. 12 houttuynoids are separated from Saururaceae Houttuynia cordata Thunb. and are all furan-flavones with novel structures. An in-vitro anti-herpes simplex virus activity screening system is used for evaluating activity of the houttuynoids, and it is found that the houttuynoids can effectively inhibit a herpes simplex virus; thus, the houttuynoids have effects on preventing and treating herpes simplex virus infection, can be applied to preparation of drugs used for resisting the herpes simplex virus and have good research and development prospects.

The invention provides the use of anti-herpes simplex virus drug acyclovir in preventing or / and treating delayed diarrhea caused by an anti-tumor drug, and the use of a drug for intestinal dysfunction caused by diarrhea, wherein the anti-tumor Drug refers to irinotecan or its active metabolite 7‑ethyl‑10‑hydroxycamptothecin (SN‑38). In the present invention, the acyclovir has clear pharmacological effects, can effectively relieve delayed diarrhea, and protect intestinal function.